TP53 mutations in human cancers: origins, consequences, and clinical use.

Cited by (1,002)

Items 101–200 of 1,002

1. The Transcription Factor FOXM1 (Forkhead box M1)
   Inken Wierstra · 2013 · Advances in cancer research
2. MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors
   Rui Gradiz, Henriqueta Coimbra Silva, Lina Carvalho, Maria Filomena Botelho, Anabela Mota‐Pinto · 2016 · Scientific Reports
3. Checkpoint Responses to DNA Double-Strand Breaks
   David P. Waterman, James E. Haber, Marcus Bustamante Smolka · 2020 · Annual Review of Biochemistry
4. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
   Sandra Assoun, Nathalie Théou–Anton, Marina Nguenang, Aurélie Cazes, Claire J. Danel, Baptiste Abbar, Johan Pluvy, Valérie Gounant, Antoine Khalil, Céline Namour et al. · 2019 · Lung Cancer
5. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants
   Cristina Fortuño, Kristy Lee, Magali Olivier, Tina F. Pesaran, Phuong L. Mai, Kelvin C. de Andrade, Laura Donatella Attardi, Stephanie B. Crowley, D. Gareth Evans, Bing Feng et al. · 2020 · Human Mutation
6. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity
   Guo, Gang, Yu, Miao, Xiao, Wei, Celis, Esteban, Cui, Yan · 2017 · Cancer Research
7. Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos
   Tamara Potapova, Jin Zhu, Rong Li · 2013 · Cancer and Metastasis Reviews
8. TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
   Naval Guastad Daver, Abhishek Maiti, Tapan Mahendra Kadia, Paresh Vyas, Ravindra Majeti, Andrew H. Wei, Guillermo Garcia‐Manero, Charles Craddock, David Andrew Sallman, Hagop M. Kantarjian · 2022 · Cancer Discovery
9. TP53Mutations in Breast and Ovarian Cancer
   Laxmi Silwal‐Pandit, Anita Langerød, Anne‐Lise Børresen‐Dale · 2016 · Cold Spring Harbor Perspectives in Medicine
10. Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclax
    Kim, Kunhwa, Maiti, Abhishek, Loghavi, Sanam, Pourebrahim, Rasoul, Kadia, Tapan M., Rausch, Caitlin R., Furudate, Ken, Daver, Naval G., Alvarado, Yesid, Ohanian, Maro et al. · 2021 · Cancer
11. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
    H-A Hou, W-C Chou, Y-Y Kuo, C-Y Liu, Liang‐In Lin, M-H Tseng, Y-C Chiang, M-C Liu, C-W Liu, J-L Tang et al. · 2015 · Blood Cancer Journal
12. Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
    Jia‐Cheng Lu, Pengfei Zhang, Xiaoyong Huang, Xiao-Jun Guo, Chao Gao, Haiying Zeng, Yi-Min Zheng, Siwei Wang, Jiabin Cai, Qi‐Man Sun et al. · 2021 · Journal of Hematology & Oncology
13. The role of DNA damage responses in p53 biology
    Daniel Speidel · 2015 · Archives of Toxicology
14. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis
    Yan Stein, Varda Rotter, Ronit Aloni-Grinstein · 2019 · International Journal of Molecular Sciences
15. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute
    Kelvin C. de Andrade, Elaine E. Lee, Elise M. Tookmanian, Chimene A. Kesserwan, James J. Manfredi, Jessica N. Hatton, Jennifer K. Loukissas, Jiří Zavadil, Lei Ji Zhou, Magali Olivier et al. · 2022 · Cell Death and Differentiation
16. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
    Tae‐Min Kim, Seung‐Hyun Jung, Chang Hyeok An, Sung Hak Lee, In-Pyo Baek, Min Sung Kim, Sung‐Won Park, Je‐Keun Rhee, Sug-Hyung Lee, Yeun‐Jun Chung · 2015 · Clinical Cancer Research
17. Germline TP53 Variants and Susceptibility to Osteosarcoma
    Mirabello, Lisa, Yeager, Meredith, Mai, Phuong L., Gastier-Foster, Julie M., Gorlick, Richard, Khanna, Chand, Patiño-Garcia, Ana, Sierrasesúmaga, Luis, Lecanda, Fernando, Andrulis, Irene L. et al. · 2015 · JNCI Journal of the National Cancer Institute
18. GermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome
    Junne Kamihara, Huma Q. Rana, Judy Ellen Garber · 2014 · Human Mutation
19. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
    Fang, Douglas D., Tang, Qiuqiong, Kong, Yanhui, Wang, Qixin, Gu, Jiaxing, Fang, Xu, Zou, Peng, Rong, Tao, Wang, Jingwen, Yang, Dajun et al. · 2019 · Journal for ImmunoTherapy of Cancer
20. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents
    Canon, Jude, Osgood, Tao, Olson, Steven H., Saiki, Anne Y., Robertson, Rebecca, Yu, Dongyin, Eksterowicz, John, Ye, Qiuping, Jin, Lixia, Chen, Ada et al. · 2015 · Molecular Cancer Therapeutics
21. p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome
    Benjamin T. Spike, Geoffrey M. Wahl · 2011 · Genes & Cancer
22. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors
    Claudia Bustamante Levy, Ana Carolina Stumbo, Ana Paula Dinis Ano Bom, Elisabeth A. Portari, Yraima Carneiro, Jerson Lima Silva, C. V. de Moura Gallo · 2010 · The International Journal of Biochemistry & Cell Biology
23. Polyamines: their significance for maintaining health and contributing to diseases
    Mengjuan Xuan, Xinyu Gu, Juan Li, Di Huang, Xue Chen, Yuting He · 2023 · Cell Communication and Signaling
24. p53 β-hydroxybutyrylation attenuates p53 activity
    Kun Liu, Fangzhou Li, Qianqian Sun, Ning Lin, Haichao Han, Kaiqiang You, Feng Tian, Zebin Mao, Tingting Li, Tanjun Tong et al. · 2019 · Cell Death and Disease
25. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
    Hu, Hai-feng, Ye, Zeng, Qin, Yi, Xu, Xiao-wu, Yu, Xian-jun, Zhuo, Qi-feng, Ji, Shun-rong · 2021 · Acta Pharmacologica Sinica
26. Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
    Hong Shen, Carl G. Maki · 2011 · Current Pharmaceutical Design
27. Oncogenic MicroRNAs: Key Players in Malignant Transformation
    Tania Frixa, Sara Donzelli, Giovanni Blandino · 2015 · Cancers
28. Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner
    Guen Tae Kim, Se Hee Lee, Jong‐Il Kim, Young Min Kim · 2014 · International Journal of Molecular Medicine
29. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review
    Gerald N. Wogan, Thomas W. Kensler, John D. Groopman · 2011 · Food Additives & Contaminants Part A
30. Accumulation of Somatic Mutations in TP53 in Gastric Epithelium With Helicobacter pylori Infection
    Takahiro Shimizu, Hiroyuki Marusawa, Yuko Mizuno Matsumoto, Tadashi Inuzuka, Atsuyuki Ikeda, Yosuke Fujii, Sachiko Minamiguchi, Shin’ichi Miyamoto, Tadayuki Kou, Yoshiharu Sakai et al. · 2014 · Gastroenterology
31. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
    Neil T. Pfister, Vitalay Fomin, Kausik Regunath, Jeffrey Y. Zhou, Wen Zhou, Laxmi Silwal‐Pandit, William A. Freed-Pastor, Oleg Laptenko, Suat Peng Neo, Jill Bargonetti et al. · 2015 · Genes & Development
32. Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression
    Orit Karni-Schmidt, Mireia Castillo-Martín, Tian HuaiShen, Nataliya Gladoun, Josep M. Domingo Domenech, Marta Sänchez‐Carbayo, Yingchun Li, Scott W. Lowe, Carol L. Prives, Carlos Cordon‐Cardo · 2011 · American Journal Of Pathology
33. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
    Chi Young Ok, Keyur Pravinchandra Patel, Guillermo Garcia‐Manero, Mark J. Routbort, Jie Peng, Guilin Tang, Maitrayee Goswami, Ken H. Young, Rajesh R. Singh, Leonard Jeffrey Medeiros et al. · 2015 · Journal of Hematology & Oncology
34. "Liquid biopsy"-ctDNA detection with great potential and challenges.
    Mingwei Ma, Hongcheng Zhu, Chi Zhang, Xinchen Sun, Xianshu Gao, Gang Chen · 2015 · Europe PMC (PubMed Central)
35. Organoid based personalized medicine: from bench to bedside
    Yaqi Li, Peiyuan Tang, Sanjun Cai, Junjie Peng, Guoqiang Hua · 2020 · Cell Regeneration
36. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53
    Neil T. Pfister, Carol L. Prives · 2016 · Cold Spring Harbor Perspectives in Medicine
37. Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue
    Shi, Jianxin, Marconett, Crystal N., Duan, Jubao, Hyland, Paula L., Li, Peng, Wang, Zhaoming, Wheeler, William, Zhou, Beiyun, Campan, Mihaela, Lee, Diane S. et al. · 2014 · Nature Communications
38. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes
    Kim E. Kortekaas, Esther Bastiaannet, Helena C. van Doorn, Peggy J. de Vos van Steenwijk, Patricia C. Ewing‐Graham, Carien L. Creutzberg, Kadir Akdeniz, Linda Suzanne Nooij, Sjoerd H. van der Burg, Tjalling Bosse et al. · 2020 · Gynecologic Oncology
39. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)
    Boon Shing Tan, Kai Hung Tiong, Heng Lungh Choo, Felicia Fei‐Lei Chung, Ling‐Wei Hii, S H Tan, I KS Yap, Sarita Pani, N TW Khor, Shew Fung Wong et al. · 2015 · Cell Death and Disease
40. MicroRNA‐17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways
    Hyun Yong Jin, Hiroyo Oda, Maoyi Lai, Rebecca L. Skalsky, Kelly J. Bethel, Jovan Shepherd, Seung Goo Kang, Wen‐Hsien Liu, Mohsen Sabouri-Ghomi, Bryan R. Cullen et al. · 2013 · The EMBO Journal
41. The disulfide compound α-lipoic acid and its derivatives: A novel class of anticancer agents targeting mitochondria
    Bastian Dörsam, Jörg Fahrer · 2015 · Cancer Letters
42. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment
    Yan Ru Cui, Gang Guo · 2016 · International Journal of Molecular Sciences
43. The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure
    Eléonore Toufektchan, Franck Toledo · 2018 · Cancers
44. Cancer biomarker discovery: Current status and future perspectives
    Katrin Mäbert, Monica Cojoc, Claudia Peitzsch, Ina Kurth, Serhiy Souchelnytskyi, Anna Dubrovska · 2014 · International Journal of Radiation Biology
45. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers
    Anne Maria Schultheis, Luciano Gastón Martelotto, Maria Rosaria De Filippo, Salvatore Piscuglio, Charlotte K.Y. Ng, Yaser R. Hussein, Jorge Sergio Reis-Filho, Robert A. Soslow, Britta Weigelt · 2015 · International Journal of Gynecological Pathology
46. Contemporary Sarcoma Diagnosis, Genetics, and Genomics
    Inga‐Marie Schaefer, Gregory Michael Cote, Jason L. Hornick · 2017 · Journal of Clinical Oncology
47. The roles and regulation of MDM2 and MDMX: it is not just about p53
    Alyssa M. Klein, Rafaela Muniz de Queiroz, Divya Venkatesh, Carol L. Prives · 2021 · Genes & Development
48. Highly Selective and Sensitive Electrochemiluminescence Biosensor for p53 DNA Sequence Based on Nicking Endonuclease Assisted Target Recycling and Hyperbranched Rolling Circle Amplification
    Linlin Yang, Yingzhou Tao, Guiyin Yue, Ruibao Li, Bin Qiu, Longhua Guo, Zhenyu Lin, Huanghao Yang · 2016 · Analytical Chemistry
49. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
    Maja J.A. de Jonge, Vincent A. de Weger, Mark Andrew Dickson, Marlies H.G. Langenberg, Axel Le Cesne, Andrew J. Wagner, Karl Hsu, Wei Zheng, Sandrine Macé, Gilles Tuffal et al. · 2017 · European Journal of Cancer
50. Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine
    Sanjay Saxena, Biswajit Jena, Neha Gupta, Suchismita Das, Deepaneeta Sarmah, Pallab Bhattacharya, Tanmay Nath, Sudip Paul, Mostafa M. Fouda, Manudeep K. Kalra et al. · 2022 · Cancers
51. Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer
    Ting Ni, Xiao-Yan Li, Na Lu, Teng An, Zhiping Liu, Rong Fu, Wen-Cong Lv, Yi-Wei Zhang, Xiao-Jun Xu, R. Grant Rowe et al. · 2016 · Nature Cell Biology
52. Ribosomal DNA copy number amplification and loss in human cancers is linked to tumor genetic context, nucleolus activity, and proliferation
    Meng Wang, Bernardo Lemos · 2017 · PLoS Genetics
53. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
    Shuangying Li, Liangliang Wang, Yuanyuan Wang, Changyi Zhang, Zhenya Hong, Zhiqiang Han · 2022 · Journal of Hematology & Oncology
54. The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation
    Liang Chen, Farooq Rashid, Abdullah Shah, Hassaan Mehboob Awan, Mingming Wu, An Liu, Jun Wang, Tao Zhu, Zhaofeng Luo, Ge Shan · 2015 · Proceedings of the National Academy of Sciences
55. Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies
    Yue Zhao, Qiongzhu Dong, Jiahui Li, Kaili Zhang, Jie Qin, Jiangang Zhao, Qiye Sun, Zhefang Wang, Thomas Wartmann, Karl Walter Jauch et al. · 2018 · Seminars in Cancer Biology
56. 5′-3′-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage
    Chen, Jing, Kastan, Michael B. · 2010 · Genes &amp; Development
57. DNA Mismatch Repair and Oxidative DNA Damage: Implications for Cancer Biology and Treatment
    Gemma Bridge, Sukaina Rashid, Sarah A. Martin · 2014 · Cancers
58. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
    Schauer, Nathan J., Liu, Xiaoxi, Magin, Robert S., Doherty, Laura M., Chan, Wai Cheung, Ficarro, Scott B., Hu, Wanyi, Roberts, Rebekka M., Iacob, Roxana E., Stolte, Björn et al. · 2020 · Scientific Reports
59. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications
    Rui Kamada, 侑 戸口, Takao Nomura, Toshiaki Imagawa, Kazuyasu Sakaguchi · 2015 · Biopolymers
60. Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies
    Richa Rathore, Brian Andrew Van Tine · 2021 · Journal of Clinical Medicine
61. Regulation of cellular senescence via the FOXO 4‐p53 axis
    Benjamin M. R. Bourgeois, Tobias Madl · 2018 · FEBS Letters
62. The p53 C Terminus Controls Site-Specific DNA Binding and Promotes Structural Changes within the Central DNA Binding Domain
    Oleg Laptenko, Idit Shiff, William A. Freed-Pastor, Andrew Zupnick, Melissa Mattia, Ella Freulich, Inbal Shamir, Noam Kadouri, Tamar Kahan, James J. Manfredi et al. · 2015 · Molecular Cell
63. Interaction of nanoparticles with biological macromolecules: a review of molecular docking studies
    Abdallah S. Abdelsattar, Alyaa Dawoud, Mohamed A. Helal · 2020 · Nanotoxicology
64. DNA repair and aging: The impact of the p53 family
    Nicolai, Sara, Rossi, Antonello, Di Daniele, Nicola, Melino, Gerry, Annicchiarico-Petruzzelli, Margherita, Raschellà, Giuseppe · 2015 · Aging
65. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
    Anna Margrét Halldórsdóttir, A Lundin, F Murray, Larry Mansouri, Sakari Knuutila, Christer Sundström, A Laurell, Hans Ehrencrona, Birgitta Sander, Richard Rosenquist · 2011 · Leukemia
66. Secondary malignancies in pediatric cancer survivors: Perspectives and review of the literature
    Daniel K. Choi, Irene Helenowski, Nobuko Hijiya · 2014 · International Journal of Cancer
67. p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
    Shyhmin Huang, Sergi Benavente, Eric A. Armstrong, Chunrong Li, Deric L. Wheeler, Paul M. Harari · 2011 · Cancer Research
68. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
    Sophie C. Postel-Vinay, Elsa Vanhecke, Ken André Olaussen, Christopher J. Lord, Alan Ashworth, Jean‐Charles Soria · 2012 · Nature Reviews Clinical Oncology
69. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
    Guillermo Valdivia, Ángela Alonso‐Diez, María Dolores Pérez Alenza, L. Peña · 2021 · Frontiers in Veterinary Science
70. Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity
    Enrico Desideri, Rolando Vegliante, Maria Rosa Ciriolo · 2014 · Cancer Letters
71. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome
    Paul Matthew Neilsen, Jacqueline E. Noll, Rachel J. Suetani, Renèe B. Schulz, Fares Al‐Ejeh, Andreas Evdokiou, David Philip Lane, David Frederick Callen · 2011 · Oncotarget
72. Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
    Kalliopi Tsafou, Purushottam Babu Tiwari, Julie Deborah Forman-Kay, Steven J. Metallo, Jeffrey A. Toretsky · 2018 · Journal of Molecular Biology
73. Driver mutations in USP8 wild-type Cushing’s disease
    Silviu Sbiera, Luis Gustavo Perez‐Rivas, Lyudmyla Taranets, Isabel Weigand, Jörg Flitsch, Elisabeth Graf, Camelia‐Maria Monoranu, Wolfgang Saeger, Christian Hagel, Jürgen Bernd Honegger et al. · 2019 · Neuro-Oncology
74. Non‐muscle myosins in tumor progression, cancer cell invasion, and metastasis
    Jessica L. Ouderkirk, Mira Krendel · 2014 · Cytoskeleton
75. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53
    Magdalena Wienken, Antje Dickmanns, Alice Nemajerová, Daniela Kramer, Zeynab Najafova, Miriam Weiss, Oleksandra Karpiuk, Moustapha S Kassem, Yanping Zhang, Guillermina Lozano et al. · 2015 · Molecular Cell
76. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
    Ori Hassin, Nishanth Belugali Nataraj, Michal Shreberk‐Shaked, Yael Aylon, Rona D. Yaeger, Giulia Fontemaggi, Saptaparna Mukherjee, Martino Maddalena, Adi Seligman, Ortal Iancu et al. · 2022 · Nature Communications
77. Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
    MichaelP Kim, Yun Zhang, Guillermina Lozano · 2015 · Frontiers in Oncology
78. WEE1 Inhibitor: Clinical Development
    Anthony H. Kong, Hisham Mohamed Mehanna · 2021 · Current Oncology Reports
79. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches
    Nadeem Riaz, Luc G.T. Morris, William Lee, Timothy An-thy Chan · 2014 · Genes & Diseases
80. Deciphering UV‐induced DNA Damage Responses to Prevent and Treat Skin Cancer
    Jihoon William Lee, Kajan Ratnakumar, Kai‐Feng Hung, Daiki Rokunohe, Masaoki Kawasumi · 2020 · Photochemistry and Photobiology
81. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53
    Shengliang Zhang, Lanlan Zhou, Bo Hong, A. Pieter J. van den Heuvel, Varun V. Prabhu, Noel A. Warfel, Christina Leah B. Kline, David T. Dicker, Levy Kopelovich, Wafik S. El‐Deiry · 2015 · Cancer Research
82. Identification of 12 cancer types through genome deep learning
    Yingshuai Sun, Sitao Zhu, Kailong Ma, Weiqing Liu, Yue Yao, Gang Hu, Huifang Lü, Wenbin Chen · 2019 · Scientific Reports
83. DNA Nanostructures and DNA‐Functionalized Nanoparticles for Cancer Theranostics
    Fay Nicolson, Akbar Ali, Moritz F. Kircher, Suchetan Pal · 2020 · Advanced Science
84. Network Pharmacology, Molecular Docking and Molecular Dynamics to Explore the Potential Immunomodulatory Mechanisms of Deer Antler
    Lingyu Liu, Yu Jiao, Mei Jun Yang, Lei Wu, Guohui Long, Wei Hu · 2023 · International Journal of Molecular Sciences
85. Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism
    Laura E. Wohak, Annette M. Krais, Jill E. Kucab, Julia Stertmann, Steinar Øvrebø, Albrecht Seidel, David H. Phillips, Volker Manfred Arlt · 2014 · Archives of Toxicology
86. Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis
    Italo Mario Cesari, Érika Carvalho, Mariana Figueiredo Rodrigues, Bruna dos Santos Mendonça, Nívea Dias Amoêdo, Franklin David Rumjanek · 2014 · International Journal of Cell Biology
87. The p53-Estrogen Receptor Loop in Cancer
    Crystal E. Berger, Yuyang Qian, Xinxin Chen · 2013 · Current Molecular Medicine
88. A second chance for telomerase reverse transcriptase in anticancer immunotherapy
    Maurizio Zanetti · 2016 · Nature Reviews Clinical Oncology
89. Comparative oncology: overcoming human cancer through companion animal studies
    Ji Hoon Oh, Je‐Yoel Cho · 2023 · Experimental & Molecular Medicine
90. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
    Xiaoli Ma, Gwénaël Le Teuff, Benjamin Lacas, Ming‐Sound Tsao, Stephen L. Graziano, Jean‐Pierre Pignon, Jean-Yves Douillard, Thierry Le Chevalier, Lesley Seymour, Martin Filipits et al. · 2016 · Journal of Thoracic Oncology
91. Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis
    Kelvin C. de Andrade, Megan N. Frone, Talía Wegman-Ostrosky, Payal P. Khincha, Jung Kim, Amina Amadou, Karina Miranda Santiago, Fernanda P. Fortes, Nathanaël Lemonnier, Lisa J. Mirabello et al. · 2018 · Human Mutation
92. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database
    Victor D. Li, Karen Hoi Lam Li, John T. Li · 2018 · Journal of Cancer Research and Clinical Oncology
93. The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy
    Mitsuhiro Nakamura, Takeshi Obata, Takiko Daikoku, Hiroshi Fujiwara · 2019 · International Journal of Molecular Sciences
94. Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
    Hyo Jeong Kang, Sung‐Min Chun, Kyu-Rae Kim, Insuk Sohn, Chang Ohk Sung · 2013 · PLoS ONE
95. Antagonistic Pleiotropy in Human Disease
    Sean Byars, Konstantinos Voskarides · 2019 · Journal of Molecular Evolution
96. Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma
    Yunli Zhou, Xun Zhang, Anne Klibanski · 2013 · Molecular and Cellular Endocrinology
97. p53 in neurodegenerative diseases and brain cancers
    Frédéric Checler, Cristine Alvès da Costa · 2013 · Pharmacology & Therapeutics
98. MicroRNAs in the DNA Damage/Repair Network and Cancer
    Alessandra Tessitore, Germana Cicciarelli, Filippo Del Vecchio, Agata Gaggiano, Daniela Verzella, Mariafausta Fischietti, Davide Vecchiotti, Daria Capece, Francesca Zazzeroni, Edoardo Alesse · 2014 · International Journal of Genomics
99. Simulating Next-Generation Sequencing Datasets from Empirical Mutation and Sequencing Models
    Zachary D. Stephens, Matthew E. Hudson, Liudmila Sergeevna Mainzer, Morgan L. Taschuk, Matthew Weber, Ravishankar K. Iyer · 2016 · PLoS ONE
100. Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo
     Ming Kei Lee, Wei Wei Teoh, Beng Hooi Phang, Wei Tong, Zhao Qi Wang, Kanaga Sabapathy · 2012 · Cancer Cell